The results of a phase 2 trial of MSD’s ROR1 inhibitor zilovertamab vedotin (zilo-V) back up the company's decision to push the antibody-drug conjugate (ADC) into a phase 3 programme.

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma (DLBCL), cementing the antibody-drug conjugate ...

BR111 is an antibody-drug conjugate (ADC) targeting dual epitopes of ROR1, intended for the treatment of ROR1-positive hematological malignancies and solid tumors. ROR1 is a transmembrane receptor ...

IM-1021 is an optimized, ROR1-targeted ADC that incorporates Immunome’s proprietary TOP1 inhibitor, HC74. The Phase 1 trial ...

Radiance Biopharma Inc. bought its way into the ROR1 antibody-drug conjugate (ADC) space through a potential $1 billion-plus licensing deal, including a $15 million up-front payment, with CSPC ...

First patient dosed in Phase 1 clinical trial evaluating IM-1021, a ROR1-targeted ADC. IND submitted in March 2025 for IM-3050, a FAP-targeted radioligand therapy. "Immunome’s efficient ...

IM-1021 is an optimized, ROR1-targeted ADC that incorporates Immunome’s proprietary TOP1 inhibitor, HC74. The Phase 1 trial is an open-label, multicenter dose escalation and expansion study ...

BR111 is an antibody-drug conjugate (ADC) targeting dual epitopes of ROR1, intended for the treatment of ROR1-positive hematological malignancies and solid tumors. ROR1 is a transmembrane receptor ...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer ...